Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives).
about
13-methyltetradecanoic acid exhibits anti-tumor activity on T-cell lymphomas in vitro and in vivo by down-regulating p-AKT and activating caspase-3Therapeutic interventions for Burkitt lymphoma in childrenHigh-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adultsOral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study.Management of non-Hodgkin's lymphomas.Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting?Primary breast peripheral T-cell lymphoma not otherwise specified: report of a case.The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell NeoplasmsIdentification and characterization of peripheral T-cell lymphoma-associated SEREX antigensAutologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey.New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas.Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.How to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models?Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature.Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin.Hematopoietic stem cell transplantation in peripheral T-cell lymphomas.Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma.A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma.Chimeric antigen receptor T-cell therapies for lymphoma.Investigational drugs for T-cell lymphoma.Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma.Synchronous diffuse large B cell lymphomas of the endometrium and breast: a staging dilemma.Peripheral T-cell lymphoma in children and adolescents: role of bone marrow transplantation.Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas.The usefulness of cell surface markers in predicting the prognosis of non-Hodgkin's lymphomas.Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas.Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial.High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas.T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors.Peripheral T-cell lymphoma, not otherwise specified.Recent advances in understanding and managing T-cell lymphoma.Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study.
P2860
Q21133027-F18504FB-CB5C-4AF3-BE20-B14D6BB0C94AQ24235495-BA82CDDB-9AC6-4ADC-93A0-D729C9610F47Q24242089-6B7285E3-F193-4D2D-8C1B-8E97D993EB29Q33396356-BAAE7B5D-CFB7-45A8-8AAE-B16B5665FD93Q33682014-DC6389C3-AA37-4F31-A961-967BFADB58AAQ33822764-F61D0401-7457-4C9A-8E41-2601A4586B3FQ34690890-43AA85E5-F3B0-44A3-9065-BFB8E2434460Q35163220-069FCB9A-64FA-435B-B65B-089696EFEE78Q35181261-BD75E81E-A0E0-41E3-B893-2B7D5499979BQ35608203-671D9EB0-19ED-417A-ADD8-85393333C3F2Q35703714-D86E9779-23C4-4D60-9698-BCFB8E3CB5F2Q35989647-017D1DB0-1ECA-481B-A975-F4AAF29729C4Q36231758-7C4A6109-454C-446C-8D11-827EA13E7785Q36355093-F3A87171-0AE5-4571-92DA-3979479DA226Q36640837-1FA44E60-BCD3-47C5-818C-8C9AAEB6A666Q36771221-BCAB4A13-4D3B-4902-A26C-9E9CDCBBA885Q36911495-CB6E5C7E-5375-4BFB-9E4E-2F6E68555B81Q37321943-FD23130C-5B9C-41EA-976A-03A47993C90BQ37355651-1A6B4DE7-B495-4D65-A87E-75149816E1C9Q37956318-DEA71BD5-D70B-425F-9CCA-C62A9ADD7584Q38600697-14661C96-5074-4C31-9241-26E9694AE133Q38635909-6325A2A2-4B6D-4B1C-AAF6-8CE92360F66EQ38944954-7ACC0162-3E76-42BD-A932-DAC7AFD5E394Q39282440-AAA9E689-EBDC-466A-A23B-62BA7D26D2A3Q40628266-FA793372-1D62-48BA-A8A0-93DA3240B1FFQ40834336-E4431D5D-0FF5-41D5-8383-4C6C7AB9DC38Q40905159-148ACFDC-4D78-4F7B-967E-30D063560E2EQ41928592-37800F90-922B-4D59-BFE8-6BC68A7B93FAQ43473775-7E7E1F52-D7DB-44F1-A057-EBA561DD8F7AQ43613022-159ABF31-F991-4BAA-B576-199F9DD1D27CQ44086093-C9C2F6F5-CE51-4E7A-BBD7-C05C08315207Q47112210-A2F9125D-D2D7-4945-AF16-E78165E0ACEEQ47131247-70F6B27E-F418-4CED-9267-7F06C5A45CE9Q48185230-7C806508-6080-4D42-AD70-DE1B75B41971Q48650246-D69ABD50-235E-46B6-941A-1A65CDD4E860
P2860
Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives).
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh
1990年學術文章
@zh-hant
name
Peripheral T-cell lymphomas ha ...... ude des Lymphomes Agressives).
@en
Peripheral T-cell lymphomas ha ...... h the LNH-84 regimen. The GELA
@nl
type
label
Peripheral T-cell lymphomas ha ...... ude des Lymphomes Agressives).
@en
Peripheral T-cell lymphomas ha ...... h the LNH-84 regimen. The GELA
@nl
prefLabel
Peripheral T-cell lymphomas ha ...... ude des Lymphomes Agressives).
@en
Peripheral T-cell lymphomas ha ...... h the LNH-84 regimen. The GELA
@nl
P2093
P1433
P1476
Peripheral T-cell lymphomas ha ...... ude des Lymphomes Agressives).
@en
P2093
B Coiffier
C Gisselbrecht
M Peuchmaur
P356
10.1093/OXFORDJOURNALS.ANNONC.A057673
P577
1990-01-01T00:00:00Z